Clinical evaluation of HuDo-CSPG4 DNA electroporation as adjuvant treatment for canine oral malignant melanoma: comparison of two vaccination protocols.

• Tác giả: Paolo Buracco, Mariateresa Camerino, Federica Cavallo, Alfredo Dentini, Erica Ilaria Ferraris, Davide Giacobino, Selina Iussich, Luca Manassero, Lorella Maniscalco, Marina Martano, Emanuela Morello, Federica Riccardo, Lidia Tarone
• Ngôn ngữ: eng
• Ký hiệu phân loại: 615.908 Treatment of poisoning
• Thông tin xuất bản: England : The veterinary quarterly , 2025
• Bộ sưu tập: NCBI
• ID: 693684

Tóm tắt

Canine oral malignant melanoma (OMM) is an aggressive, spontaneously occurring tumor carrying a poor to guarded prognosis and relatively limited therapeutic strategies. In this landscape, chondroitin sulfate proteoglycan (CSPG)4 represents a promising immunotherapeutic target. The objective of this bi-center prospective study was to examine the clinical outcome of OMM-bearing dogs treated with surgery and adjuvant electroporation using a DNA vaccine (HuDo-CSPG4) encoding both human (Hu) and canine (Do) portions of CSPG4 through two different vaccination protocols. Dogs with stage I-III surgically resected CSPG4-positive OMM underwent HuDo-CSPG4 plasmid electroporation starting at the 3